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Abstract
Background: Co-infection with human immunodeficiency virus-1 (HIV-1) and hepatitis C virus (HCV) is associated
with faster progression of liver disease and an increase in HCV persistence. However, the mechanism by which HIV-
1 accelerates the progression of HCV liver disease remains unknown.
Results: HIV-1/HCV co-infection is associated with increased expression of interferon gamma-induced protein-10
(IP-10) mRNA in peripheral blood mononuclear cells (PBMCs). HCV RNA levels were higher in PBMCs of patients
with HIV-1/HCV co-infection than in patients with HCV mono-infection. HIV-1 Tat and IP-10 activated HCV
replication in a time-dependent manner, and HIV-1 Tat induced IP-10 production. In addition, the effect of HIV-1
Tat on HCV replication was blocked by anti-IP-10 monoclonal antibody, demonstrating that the effect of HIV-1 Tat
on HCV replication depends on IP-10. Taken together, these results suggest that HIV-1 Tat protein activates HCV
replication by upregulating IP-10 production.
Conclusions: HIV-1/HCV co-infection is associated with increased expression of IP-10 mRNA and replication of HCV
RNA. Furthermore, both HIV-1 Tat and IP-10 activate HCV replication. HIV-1 Tat activates HCV replication by
upregulating IP-10 production. These results expand our understanding of HIV-1 in HCV replication and the
mechanism involved in the regulation of HCV replication mediated by HIV-1 during co-infection.
Background
Hepatitis C virus (HCV) is a major etiological agent of
chronic liver disease. An estimated 180 million humans
are infected with HCV worldwide. Due to similar routes
of transmission, co-infection with HCV and human
immunodeficiency virus-1 (HIV-1) is common, with the
prevalence of co-infection ranging from 4 to 5 million
patients [1]. HCV-related liver diseases have become a
major source of morbidity and mortality in HIV-1-
infected patients [2]. Once chronic infection is estab-
lished, patients with HIV-1/HCV co-infection have a
higher rate of viral persistence, faster progression, and
earlier development of end-stage liver disease, compared
to HCV mono-infected patients [3,4]. Infection with
HIV-1 is associated with higher HCV viral levels in sera
compared to infection with HCV alone [5]. However,
the mechanisms that accelerate progression of HCV/
HIV-1 co-infected patients are not fully understood.
HIV-1 infection enhances HCV replication, thus chan-
ging the course of HCV-related disease in co-infected
patients [6,7]. HCV was originally thought to be strictly
hepatotropic, while the main cell targets for HIV-1 infec-
tion are mononuclear leukocytes bearing CD4 and the
chemokine receptors C-C chemokine receptor type 5
(CCR5) and chemokine (C-X-C motif) receptor 4
(CXCR4). However, HCV can also replicate in peripheral
blood mononuclear cells (PBMCs), particularly in patients
with HIV-1 [8,9]. The effect of HIV-1 on PBMC cultures
of HCV mono-infected patients in vitro has previously
been investigated. The production of HCV post-HIV
infection increases by 1 to 2 logs, compared to uninfected
controls [10]. Also, HIV-1 facilitates replication of HCV in
native human macrophages in vitro [11].
The interferon g-inducible protein 10 (IP-10 or
CXCL10) is a chemotactic C-X-C chemokine that
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IP-10 is produced by a variety of cells, including astro-
cytes and hepatocytes [15,16]. Increased levels of IP-10
have been detected in the serum and liver of HCV-
infected individuals compared to controls [17,18].
Elevated IP-10 is correlated with increased liver damage
[19] and HCV viral loads [20], as well as enhanced IP-
10 levels in HIV-1 mono-infected patients compared to
controls [21]. Increased IP-10 production during HIV-1
infection has been partially attributed to HIV-1 proteins,
including HIV-1 accessory protein transactivator of
transcription (Tat), in a number of cells such as astro-
cytes and macrophages [22,23]. Serum IP-10 levels are
higher in HIV-1/HCV co-infected patients than in HCV
mono-infected patients [24].
HIV-1 Tat is a transactivating protein that contributes to
the transactivation of viral and cellular genes [25]. Extra-
cellular Tat, released from virus-infected cells, can enter
neighboring infected or uninfected cells and induce its
biological effects, including cytokine expression [26,27].
For example, extracellular Tat stimulates IL-10 expression
in human monocytes in a time- and dose-dependent man-
ner [28]. Also, Tat upregulates the expression of specific
chemokine receptors, such as CCR5 and CXCR4, which
are important for HIV-1 infection [29]. In addition to its
regulatory role in HIV-1 infection, Tat may activate
[30,31] and facilitate the invasion of viruses [32].
IP-10 mRNA levels in PBMCs from HIV-1/HCV co-
infected and HCV mono-infected patients showed that
HIV-1/HCV co-infection was associated with increased
expression of IP-10 mRNA and in the replication of HCV
RNA. Furthermore, we used two different infectious HCV
models to examine the effects of HIV-1 Tat and IP-10 on
HCV replication, which demonstrated that both HIV-1
Tat and IP-10 activate HCV replication. Also, HIV-1 Tat
activates HCV replication by upregulating IP-10 produc-
tion. The mechanism involved in the regulation of HCV
replication mediated by HIV-1 during co-infection is
discussed.
Results
IP-10 mRNA and HCV RNA levels are increased in patients
with HIV-1/HCV co-infection compared to HCV mono-
infection
We evaluated the IP-10 mRNA levels in PBMCs isolated
from healthy individuals and HCV mono-infected and
HIV-1/HCV co-infected patients. IP-10 mRNA levels
were higher in all infected patients compared to healthy
control subjects, and higher in patients with HIV-1/HCV
co-infection than in those with HCV mono-infection
(Figure 1A). Increases in serum HCV viral loads in the
HIV-1/HCV co-infected group were more common than
in the HCV mono-infected group (median levels: 6.1 ×
105 vs. 1.4 × 106 copies/ml, respectively) (Table 1). HCV
can also replicate in PBMCs [8,9], so we compared the
levels of HCV RNA in PBMCs of HCV mono-infected
and HIV-1/HCV co-infected patients. HCV RNA levels
were more than three-fold higher in HIV-1/HCV co-
infected patients than in HCV mono-infected patients
(Figure 1B). These findings are consistent with other stu-
dies, demonstrating that HCV RNA levels and viral loads
are increased in co-infected patients [33,34].
We examined correlations between IP-10 mRNA
levels and HCV RNA levels in both types of patient.
Increased IP-10 levels were positively correlated with
HCV RNA levels in both groups (Figure 1C, D).
IP-10 increases HCV replication in Huh7.5.1 cells
Chemokines, which are chemotactic cytokines, play an
important role in the pathogenesis of chronic HCV and
are useful for the clinical management of patients with
hepatitis C [35]. It is also known that chemokine CXCL-8
(interleukin-8) may enhance HCV replication [36].
We next examined the effects of IP-10 on HCV replica-
tion. Huh7.5.1 cells were infected with FL-J6/JFH-
5’C19Rluc2Aubi and incubated with phosphate buffer
solution (PBS), IP-10, or heat-inactivated IP-10 (HI-IP-10)
proteins. Treated cells were harvested and examined for
luciferase activity, which increased over time (Figure 2A).
However, luciferase activities increased from 96 to 140 h
post-treatment by exposure to IP-10, but not PBS or HI-
IP-10 (Figure 2A).
To corroborate these results, Huh7.5.1 cells were
infected with JFH1 virus, a full cell culture-infectious
genotype 2a HCV isolate [37], and then incubated with
PBS, IP-10, or HI-IP-10, respectively, for 3, 6, and 9
days. The HCV replication levels in the cellular super-
natants were measured, which showed that HCV RNA
copies increased over time in the presence of BSA, IP-
10, and HI-IP-10, respectively. However, HCV RNA
levels were elevated at 3 days and peaked at 6 days
post-treatment (Figure 2B). The intracellular levels of
HCV core protein was determined by Western blot
analyses, demonstrating that IP-10 activates HCV core
protein expression from 6 to 9 days post-treatment
(Figure 2C). All of these results suggest that IP-10 can
activate HCV replication.
Having demonstrated that the addition of IP-10 stimu-
lates HCV replication, we next wanted to determine
whether endogenous IP-10 is also involved in HCV
replication. We examined the effects of anti-IP-10 anti-
bodies on HCV replication. Huh7.5.1 cells were infected
with FL-J6/JFH-5’C19Rluc2Aubi and incubated with IP-
10 neutralizing antibody, PBS, or MSIgG (as a control).
IP-10 neutralizing antibody inhibited HCV replication
(Figure 2D). In contrast, PBS and MSIgG did not affect
HCV replication. Therefore, endogenous IP-10 is
involved in the activation of HCV replication.
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Page 2 of 12Figure 1 Analysis of IP-10 mRNA and HCV RNA levels in PBMCs isolated from healthy individuals, HCV mono-infected patients, and
HIV-1/HCV co-infected patients. (A) Transcriptional expression of IP-10 in PBMCs isolated from HCV mono-infected patients, HIV-1/HCV co-
infected patients, and healthy individuals. Data were normalized to the amount of GAPDH-specific mRNA as a reference transcript. Numbers
below each patient group (e.g. n = 24) indicate the number of persons in that group. (B) Replication of HCV RNA in PBMCs isolated from
patients with HCV mono-infection and HIV-1/HCV co-infection. Data were normalized to the amount of GAPDH-specific mRNA as a reference
transcript. (C) Correlations between the expression of IP-10 mRNA and HCV RNA in PBMCs isolated from patients with HCV mono-infection and
HIV-1/HCV co-infection. (D) Correlations between the expression of IP-10 mRNA and HCV RNA in PBMCs isolated from patients with HIV-1/HCV
co-infection. Two groups of patients were analyzed for IP-10 mRNA and HCV RNA expression. Data were subjected to linear regression analysis.
Correlation coefficients are indicated.
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HIV Tat is known to induce IP-10 production in human
astrocytes [22]. Huh7.5.1 cells were infected with or with-
out JFH1 and then treated with PBS, Tat, or heat-inacti-
vated Tat (HI-Tat), respectively. IP-10 protein levels were
detected by ELISA at different times post-treatment.
IP-10 protein levels were significantly higher in HCV-
infected cells than in uninfected cells (Figure 3A), indicat-
ing that HCV activates IP-10 expression. HIV-1 Tat
protein induced IP-10 protein production in a time-
dependent manner in both HCV-infected and uninfected
cells (Figure 3A), demonstrating that Tat can activate IP-
10 protein expression.
We next measured the IP-10 mRNA levels in Huh7.5.1
cells infected with or without JFH1 and treated with PBS,
Tat, or HI-Tat, respectively. IP-10 mRNA levels were
higher in HCV-infected cells than in uninfected cells
(Figure 3B), indicating that HCV activates IP-10 gene
expression. HIV-1 Tat protein induced IP-10 mRNA
expression in a time-dependent manner in both HCV-
infected and uninfected cells (Figure 3B), suggesting that
Tat can activate IP-10 gene expression at the transcrip-
tional level.
HIV-1 Tat protein stimulates HCV replication
Our previous study showed that Tat up-regulated HCV
replication using co-transfection assay [38]. In this study,
we assessed the effects of HIV-1 Tat protein on HCV
replication in Huh7.5.1 cells infected with FL-J6/JFH-
5’C19Rluc2Aubi and treated with PBS, Tat, or HI-Tat,
respectively. The roles of Tat in the regulation of HCV
replication were determined by measuring luciferase activ-
ities, which showed that Tat protein, but not PBS or
HI-Tat, activated HCV replication 72 h post-treatment.
The HCV replication levels activated by Tat peaked 96 h
post-treatment and then declined (Figure 4A).
We next evaluated the role of Tat in the regulation of
HCV replication using a second system. Huh7.5.1 cells
infected with JFH1 virus were incubated with PBS, Tat, or
HI-Tat, respectively. HCV RNA copies were measured in
the cell culture supernatant, which showed that HCV
RNA copies increased over time until 6 days post-treat-
ment (Figure 4B). The HCV RNA levels were elevated in
the presence of Tat, but not in the presence of PBS or
HI-Tat (Figure 4B), indicating that HIV-1 Tat protein sti-
mulates HCV RNA replication. The HCV core protein
levels were also measured by Western blot analyses, indi-
cating that core protein levels increased over time until 6
days post-treatment (Figure 4C). In addition, HCV core
protein levels were elevated in the presence of Tat, but not
in the presence of PBS or HI-Tat (Figure 4C), suggesting
that HIV-1 Tat protein can activate HCV core protein
expression.
Anti-IP-10 antibodies block the activation of HCV
replication regulated by HIV-1 Tat
Both HIV-1 Tat and IP-10 enhance HCV replication, and
HIV-1 Tat can increase IP-10 expression levels in hepato-
cytes. However, whether HIV-1 Tat activation of HCV
replication is dependent on IP-10 remains unknown.
Huh7.5.1 cells infected with FL-J6/JFH-5’C19Rluc2AUbi
were incubated with PBS, Tat, Tat plus MSIgG, or Tat
plus anti-IP-10 neutralizing antibodies. HIV-1 Tat protein
activated HCV replication in Huh7.5.1 cells treated with
PBS or MSIgG, but not in cells treated with anti-IP-10
neutralizing antibodies (Figure 5). Taken together, these
Table 1 Summary of patient characteristics
HCV HCV/HIV
Mono-infected Co-infected
Characteristic (n = 20) (n = 17)
Gender
Female 8 0
Male 12 17
Age (years) 37 (26-60) 34 (28-38)
ALT level (IU/L) 40.6 (14-118) 9 (2-25)
AST level (IU/L) 34.8 (17-116) 52 (29-99)
CD4 count (cells/ul) NT 256 (106-474)
CD8 count (cells/ul) NT 989 (357-1600)
Serum HCV RNA (copies/ml) 6.1 × 10
5 (10
3-1.2 × 10
7) 1.4 × 10
6 (10
3-6.8 × 10
7)
HCV genotype
17 8
25 4
35 3
Unknown 3 2
Data are median (range) values, unless otherwise indicated. ALT, alanine aminotransferase; AST, aspartate aminotransferase; NT, not tested
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Page 4 of 12Figure 2 Determination of the roles of IP-10 protein in the activation of HCV replication. (A) Huh7.5.1 cells were infected with FL-J6/JFH-
5’C19Rluc2Aubi virus for 24 h, and then incubated with PBS, IP-10 (1 μg/ml), or heat-inactivated IP-10 (HI-IP-10) (1 μg/ml) in 24-well plates for
different times, as indicated. Treated cells were harvested and analyzed for luciferase activity. (B) Huh7.5.1 cells were infected with JFH1 virus, and
then incubated with PBS, IP-10, or HI-IP-10 for 9 days. Culture supernatants were harvested and HCV copy numbers were determined by real-
time PCR (RT-PCR). (C) Huh7.5.1 cells were infected with JFH1 virus, and then incubated with PBS, IP-10, or HI-IP-10 for 9 days. Cells were
harvested and analyzed for HCV core protein expression by Western blot. b-Actin expression was measured as a loading control. (D) Huh7.5.1
cells were infected with FL-J6/JFH-5’C19Rluc2Aubi virus and then incubated with PBS, 1 μg/ml MSIgG, or 1 μg/ml anti-IP-10 neutralizing antibody
for 144 h. Cells were harvested at different times as indicated and luciferase activity was assayed.
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Page 5 of 12Figure 3 Analysis of the role of HIV-1 Tat protein in the regulation of IP-10 expression. (A) Huh7.5.1 cells were infected with or without
JFH1 virus and then incubated with PBS, 1 μg/ml Tat, or 1 μg/ml heat-inactivated Tat (HI-Tat) for different times, as indicated. Cell culture
supernatants were collected and IP-10 levels were quantified by ELISA. (B) Huh7.5.1 cells were infected with or without JFH1 virus and then
incubated with PBS, 1 μg/ml Tat, or 1 μg/ml heat-inactivated Tat (HI-Tat) for different times, as indicated. Cells were collected and the levels of
IP-10 mRNA were quantified by real-time PCR (RT-PCR).
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Page 6 of 12Figure 4 Determination of the role of HIV-1 Tat protein in the activation of HCV replication. (A) Huh7.5.1 cells were infected with FL-J6/
JFH-5’C19Rluc2Aubi virus and then incubated with PBS, 1 μg/ml Tat, or 1 μg/ml HI-Tat in 24-well plates for different times, as indicated. Cells
were harvested and analyzed for luciferase activity. (B) Huh7.5.1 cells were infected with JFH1 virus and then incubated with PBS, Tat, or HI-Tat
for 9 days. Cell culture supernatants were harvested and HCV copy numbers were determined by real-time PCR (RT-PCR). (C) Huh7.5.1 cells were
infected with JFH1 virus and then incubated with PBS, Tat, or HI-Tat for 9 days. Cells were harvested and HCV core protein levels were detected
by Western blot analyses. b-actin level was determined as a loading control.
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HIV-1 Tat activates HCV replication by regulating IP-10
during HIV-1/HCV co-infection.
Discussion
Co-infection of HCV with HIV-1 is prevalent and causes
increased HCV viral loads, as well as increased morbidity
in co-infected individuals [39,40]. The precise molecular
mechanism by which HIV-1 increases HCV persistence
and accelerates liver fibrosis is unknown. Chemokines
play an important role in the pathogenesis of both HCV
and HIV-1 infections. Also, HIV-1 Tat protein is known
to activate HCV replication by upregulating IP-10
production.
Elevated IP-10 levels have been detected in HCV-
infected patients compared to healthy controls [17,18].
This association is supported by the positive correlation
between IP-10 levels and HCV viral load, as well as the
significant decrease in IP-10 levels after clearance of
HCV infection [17]. Elevated IP-10 mRNA levels were
detected in HCV mono-infected patients compared to
healthy controls. Also, increased IP-10 mRNA levels
were associated with increased HCV RNA levels in HCV-
infected patients. This indicates that IP-10 plays an
important role in the natural pathogenesis of HCV-
induced liver damage. Furthermore, IP-10 promotes
HIV-1 replication in monocyte-derived macrophages and
peripheral blood lymphocytes [41]. However, the effect of
IP-10 on HCV replication is not well understood. IP-10
upregulates HCV replication in hepatocytes in a time-
dependent manner. Treatment with an IP-10-specific
monoclonal antibody reduces HCV replication in
Huh7.5.1 cells, demonstrating that endogenous IP-10
stimulates HCV replication.
Previous studies have reported that IP-10 levels are ele-
vated in HIV-1 mono-infected patients compared to
healthy control subjects [42], and that IP-10 stimulates
HIV-1 replication [41]. Significantly higher serum IP-10
levels have been reported in HIV-1/HCV co-infected
patients than in mono-infected and uninfected control
groups [24]. This suggests that IP-10 plays an important
role in the pathogenesis of HIV-1/HCV co-infection.
However, no reports are available on the role of IP-10 in
the regulation of HIV-1/HCV co-infection. Initially, we
measured the IP-10 mRNA levels in PBMCs from a
healthy, HCV mono-infected, and HIV-1/HCV co-infected
Figure 5 Role of endogenous IP-10 in the activation of HCV replication regulated by HIV-1 Tat protein determined by antibody
depletion. Huh7.5.1 cells were infected with FL-J6/JFH-5’C19Rluc2Aubi virus and then incubated with PBS, Tat, Tat plus MSIgG, and Tat plus
anti-IP-10 neutralizing antibody, respectively, in 24-well plates for 120 h. Cells were then harvested at different times (as indicated) and luciferase
activity was assayed.
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nificantly increased IP-10 mRNA expression in PBMCs
compared to HCV mono-infection, suggesting that HIV-1
enhances IP-10 expression in HCV/HIV-1 co-infected
patients.
The transactivating effects of Tat are not limited to
HIV-1-infected cells because extracellular Tat is secreted
into the plasma of HIV-1-infected patients where it can
exert its effects on uninfected cells [43]. Extracellular Tat
non-specifically binds to cell membranes and is interna-
lized, which may induce intracellular signals that ulti-
mately change cellular gene expression. For example, Tat
upregulates the expression of a number of cytokines
(TNF-a, IL-10) [44,45] and chemokines (IL-8, IP-10)
[22]. HIV-1 Tat also induces IP-10 in astrocytes [22,46].
Our results corroborate these findings because IP-10
expression was increased in Huh7.5.1 cells in the pre-
sence of HIV-1 Tat. Also, HCV infection upregulates IP-
10 expression in Huh7.5.1 cells. This is consistent with
in vivo findings that demonstrated that IP-10 mRNA
levels were higher in HCV-infected patients than in
healthy controls. We found that Tat activates IP-10
expression and HCV replication, and that IP-10 upregu-
lates HCV replication in two infectious HCV models.
Treatment with an anti-IP-10 monoclonal antibody
reduced Tat-activated HCV replication, demonstrating
that Tat enhancement of HCV replication is dependent
on IP-10. Tat has been implicated in the activation of
cytokine transforming growth factor (TGF)-b in HIV-1-
infected cells and in the stimulation of JC virus (JCV)
gene transcription and DNA replication in oligodendro-
glia, the primary central nervous system cell type infected
by JCV in progressive multifocal leukoencephalopathy
[47]. Tat also activates Kaposi sarcoma-associated her-
pesvirus (KSHV) lytic cycle replication from latency, in
part by modulating janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathways, and
promotes KS progression [48]. HIV-1 transactivator pro-
tein Tat, produced by HIV-1-infected cells, is secreted
into the extracellular matrix where it activates a complex
cascade of signaling pathways and alters the intrahepatic
chemokine environment, particularly chemokine IP-10.
This contributes to the activation of HCV replication and
accelerates liver fibrosis observed in patients co-infected
with HIV-1 and HCV. The increased level of IP-10
induction in PBMCs from HIV-1-infected individuals
may allow for the establishment of more aggressive HCV
infection. The downregulation of anti-HCV responses
allow for increased HCV replication and higher HCV
viral loads. Tat activation of IP-10 may promote HIV-1
immunosuppression and stimulate HCV gene transcrip-
tion. Elevated IP-10 levels in HCV mono-infected
patients are correlated with increased liver disease. The
increased IP-10 levels in HCV/HIV-coinfected patients
may explain the accelerated progression to liver disease
in these individuals. IP-10 expression is also associated
with immunological treatment failure following HAART
[21]. Therefore, reducing IP-10 expression and function
may enhance the effectiveness of current anti-retroviral
treatments.
Conclusions
HIV-1/HCV co-infection is associated with a significant
increase in the expression of IP-10 mRNA in PBMCs.
HCV RNA levels were higher in PBMCs of patients with
HIV-1/HCV co-infection than in those with HCV mono-
infection. HIV-1 Tat or IP-10 activates HCV replication in
a time-dependent manner. Also, HIV-1 Tat induces IP-10
production. In addition, the effect of HIV-1 Tat on HCV
replication was blocked by anti-IP-10 monoclonal anti-
body, demonstrating that the effect of HIV-1 Tat on HCV
replication depends on IP-10. Taken together, these results
suggest that HIV-1 Tat protein activates HCV replication
by upregulating the production of the chemokine IP-10.
Thus, IP-10 may be a potential therapeutic target for the
treatment of patients with HIV-1/HCV co-infection.
Further work is necessary to determine the intermediary
pathways responsible for the effects on HCV replication.
Our study increases the understanding of the mechanisms
involved in the co-infection of two deadly viruses, HIV-1
and HCV.
Methods
Patient samples
PBMCs from 20 HCV mono-infected and 17 HIV-1/HCV
co-infected patients were obtained from local AIDS clinics
and hospitals. Patients were excluded if they were positive
for hepatitis B virus (HBV) surface antigens or had any of
the following: renal failure, hepatocellular carcinoma,
decompensated liver disease, or any cause of liver disease
other than HCV infection. The demographic information
on these patients is summarized in Table 1. PBMCs iso-
lated from the blood of 24 age-matched healthy persons
collected at a local blood donation center were used as
controls. Informed consent was obtained from all patients.
Collection of blood samples for research was approved by
the Institutional Review Board of the College of Life
Sciences, Wuhan University, China, in accordance with
the guidelines for the protection of human subjects.
Reagents
Recombinant HIV-1 Tat (ab83353) was purchased from
Abcam. Recombinant human IP-10 (266-IP-010) and
mouse immunoglobulin G (MSIgG) were purchased from
R&D Systems. Antibody against the HCV core protein (sc-
52804) and IP-10 (sc-28877) were purchased from Santa
Cruz, and antibody against b-actin (cw-0096A) was pur-
chased from CWBio.
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Huh7.5.1 cells were cultured in Dulbecco’sm o d i f i e d
eagle medium (DMEM) (Gibco BRL, USA) supplemen-
ted with 10% fetal calf serum (Gibco BRL, USA), 100 U/
ml penicillin, and 100 μg/ml streptomycin sulfate. The
cells were maintained at 37°C in a 5% CO2 incubator.
The genotype 2a HCV virus, JFH1, was prepared and
used to infect Huh7.5.1 cells, as previously reported [37].
FL-J6/JFH-5’C19Rluc2AUbi plasmid was kindly provided
by Dr. Charles M. Rice, from Rockefeller University and
FL-J6/JFH-5’C19Rluc2AUbi virus was prepared as
described previously [49]. Virus titration was measured
using a commercial kit (HCV RNA qPCR Diagnostic Kit,
KHB).
Luciferase reporter gene assay
To harvest samples for luciferase assays, cells were washed
once with phosphate buffered solution (PBS), and then
100 μl lysis buffer (Promega) was added to each well of a
24-well plate, and a 50 μl sample was mixed with lucifer-
ase assay substrate (Promega). Luciferase activity was typi-
cally measured for 10 s using a luminometer (Turner
Designs TD-20/20). Assays were performed in triplicate
and are expressed as the mean ± standard deviation (SD)
of luciferase activity.
Real-time RT-PCR
Total RNA was extracted from PBMCs or cells using
Trizol reagent (Invitrogen), according to the manufac-
turer’s protocol. DNA was removed from the sample by
on-column DNase I treatment. RNA was used as a tem-
plate to synthesize cDNA using random primers and
MMLV-RT (Promega) at 42°C for 60 min, followed by
denaturation for 10 min at 70°C. Real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) was per-
formed using SYBR Green PCR master mix (Roche)
in LightCycler 480 (Roche). After an initial incubation at
95°C for 5 min, reaction mixtures were subjected to 40
cycles of amplification under the following conditions:
94°C for 15 s, 55°C for 15 s, and 72°C for 20 s. To examine
the quality of detection primers, the fluorescence was
measured at this step, followed by a final melting curve
step from 50°C to 95°C. Primers for HCV detection were
5’-TCGTATGATACCCGATGCT-3’ (forward) and 5’-
GTTTGACCCTTGCTGTTGA-3’ (reverse). Primers for
IP10 detection were 5’-TCTAGAACCGTACGCTG-
TACCTGC-3’ (forward) and 5’-CTGGTTTTAAGGA-
GATCT-3’ (reverse). Primers for internal reference
GAPDH detection were 5’-AAGGCTGTGGGCAAGG-3’
(forward) and 5’-TGGAGGAGTGGGTGTCG-3’ (reverse).
Each sample was run in triplicate; threshold cycles (CT)
were averaged and normalized to endogenous GAPDH.
The relative amount of amplified product was calculated
using the comparative CT method (Roche).
Western blotting and ELISA
Protein was resolved on a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel and
transferred to nitrocellulose membranes (minipore).
Membranes were blocked with PBS containing 5% fat-
free milk powder and 0.1% Tween 20 for 1 h, blotted
with the appropriate primary antibodies for 2 h, incu-
bated with HRP-conjugated secondary antibody (GE) for
1 h, washed, incubated with HRP substrate luminol
reagent (Millipore), and analyzed using a Luminescent
Image Analyzer (Fujifilm LAS-4000). IP-10 protein levels
in supernatants were measured using a commercially
available enzyme-linked immunosorbent assay (ELISA)
kit (BD Biosciences).
Statistical Analyses
Data that were Gaussian distributed were analyzed by
parametric t-tests for independent samples or by analy-
sis of variance (ANOVA). Correlation coefficients were
calculated by linear regression analysis.
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reverse transcriptase polymerase chain reaction; PBS: Phosphate buffer
solution.
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